Colistimethate Sodium

Indications & Dose:

Gram-negative infections resistant to other antibacterials, including those caused by Pseudomonas aeruginosa, Acinetobacter baumanii and Klebsiella pneumoniae 

• BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION

Adult (body-weight up to 60 kg): 50 000–75 000 units/kg daily in 3 divided doses, to be administered into a totally implantable venous access device when giving via slow intravenous injection
Adult (body-weight 60 kg and above): 1–2 million units every 8 hours, to be administered into a totally implantable venous access device when giving via slow intravenous injection; maximum 6 million units per day

Adjunct to standard antibacterial therapy for Pseudomonas aeruginosa infection in cystic fibrosis

• BY INHALATION OF NEBULISED SOLUTION

Adult: 1–2 million units twice daily, adjusted according to response, increased to 2 million units 3 times daily for subsequent respiratory isolates of Pseudomonas aeruginosa

Contraindications:

Myasthenia gravis

Side Effects:

Common or very common

When used by inhalation Bronchospasm . cough . dysphonia . nausea . sore mouth . Sore throat . taste disturbances . vomiting Uncommon

When used by inhalation Hypersalivation . thirst Rare

With intravenous use Vasomotor instability

Frequency not known

With intravenous use Apnoea . confusion . headache . muscle weakness . nephrotoxicity . neurotoxicity reported especially with excessive doses . perioral paraesthesia . peripheral paraesthesia . psychosis . rash . slurred speech . vertigo . visual disturbances

Cautions:

Precautions:

Interaction:

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: